KSNM60 in Non-thyroidal Radionuclide Therapy: Leaping into the Future
10.1007/s13139-021-00703-9
- Author:
Byung Hyun BYUN
1
;
Myoung Hyoun KIM
;
Yeon-Hee HAN
;
Hwan-Jeong JEONG
Author Information
1. Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul, South Korea
- Publication Type:REVIEW
- From:Korean Journal of Nuclear Medicine
2021;55(5):203-209
- CountryRepublic of Korea
- Language:English
-
Abstract:
This year, the Korean Society of Nuclear Medicine (KSNM) is celebrating its 60th anniversary. Treatment, as well as diagnosis, has played a very important role in the development of nuclear medicine. Since I-131 was used for thyroid therapy in 1959, other radionuclide therapy is still being used, and attempts to use new radionuclide are increasing. In this review, we briefly summarize and introduce the therapies such as radioimmunotherapy, transarterial radioembolization, radionuclide therapy for neuroendocrine tumors, peptide receptor radionuclide therapy, control of metastatic bone pain, radiation synovectomy, radionuclide brachytherapy, alpha particle therapy, and boron neutron capture therapy, which has been being attempted so far in the field of nuclear medicine.
